Raffaele Giusti - Concepedia

Author

Raffaele Giusti

Also Known As

Annalisa Guida, Bartłomiej Tomasik, Federica Zoratto, Francesca Mazzoni, Giusti R, Giusti Raffaele, Giusti, Raffaele, Marco Filetti, R. Giusti, RAFFAELE GIUSTI

341

Publications

6.3K

Citations

H-Index

Concepts

All Affiliations

Sapienza University of Rome CTO Andrea Alesini Istituti di Ricovero e Cura a Carattere Scientifico University of L'Aquila University of Parma

About

Raffaele Giusti is an author at Sapienza University of Rome specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	2.1K
2	Health Sciences	5	5	462
3	Engineering	1	1	28
4	Public Health	1	1	621
5	Epidemiology	1	1	621

Raffaele Giusti

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines Marie Fallon, Raffaele Giusti, Federica Aielli, Annals of Oncology	2018	841
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang, The Lancet Oncology Virus EpidemiologyMedicineCovid-19 PandemicClinical EpidemiologyInternational Health	2020	621
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Journal for ImmunoTherapy of Cancer	2019	400
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice Alessio Cortellini, Marco Tucci, Vincenzo Adamo, Journal for ImmunoTherapy of Cancer	2020	250
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden Daniele Marinelli, Marco Mazzotta, Stefano Scalera, Annals of Oncology MedicineLung AdenocarcinomaImmunologyPathologyCancer Genomics	2020	218
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study Alessio Cortellini, Sebastiano Buti, Daniele Santini, The Oncologist ImmunologyImmunoeditingPathologyAnti-programmed Death-1 ImmunotherapyImmunotherapy	2019	214
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment Andrea Botticelli, Pamela Vernocchi, Federico Marini, Journal of Translational Medicine	2020	199
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Clinical Lung Cancer Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials	2019	174
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer Caroline A. Nebhan, Alessio Cortellini, Weijie Ma, JAMA Oncology	2021	146
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Journal for ImmunoTherapy of Cancer	2021	132

Page 1